We are a pioneering biotechnology company at the intersection of artificial intelligence and peptide therapeutics. Our mission is to revolutionize drug discovery by developing next-generation cyclic peptide drugs through a seamless integration of advanced AI algorithms and robust wet-lab validation.
Founded by a team of computational biologists, AI experts, and medicinal chemists, we aim to address unmet medical needs by tackling challenging targets, including protein-protein interactions, with unprecedented speed and precision.
Online Service
Quality Services
Satisfaction Rate
Combining generative AI with wet-lab validation to accelerate macrocyclic peptide drug design for your specific needs.
Generative models trained on vast peptide-protein interaction datasets design highly focused virtual libraries enriched for binders against your target, incorporating diverse macrocyclic scaffolds and non-canonical amino acids.
Deep learning predicts binding modes, affinities, and ADMET properties. Top candidates are virtually evolved through iterative in silico mutagenesis, drastically accelerating hit-to-lead optimization.
AI-selected peptides are synthesized and screened via our high-throughput mRNA display system. Experimental data, including structural insights, feeds back to continuously refine our AI models.
At the heart of our service is an AI-powered macrocyclic peptide discovery platform that seamlessly integrates in silico evolution with wet-lab validation.
